Overview

Clinical Study of PD-L1 Antibody (TQB2450) Plus Chemotherapy (Cisplatin and Etoposide) for Previously Untreated Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This is a phase II, non-randomized, open-label, single center study to evaluate the efficacy and safety of combining TQB2450 (PD-L1 antibody) + chemotherapy (cisplatin and etoposide) followed by TQB2450 maintenance therapy as first-line treatment in patients with extensive-stage small cell lung cancer (SCLC), and neoadjuvant TQB2450 + chemotherapy (EP) followed by radical surgery and adjuvant TQB2450 immunotherapy as first-line treatment in patients limited-stage SCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Treatments:

Cisplatin
Etoposide
Etoposide phosphate